B5063

BMS-193885

≥98% (HPLC)

• 동의어(들): 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-dimethyl ester-3,5-pyridinedicarboxylic acid
• 실험식(Hill 표기법): C₃₃H₄₂N₄O₆
• CAS Number: 186185-03-5
• Molecular Weight: 590.71
• MDL number: MFCD16878998
• UNSPSC 코드: 12352200
• PubChem Substance ID: 329773248
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 형태: powder
• 색상: light yellow to yellow
• solubility: DMSO: >10 mg/mL
• 주관자: Bristol-Myers Squibb
• 저장 온도: −20°C
• SMILES string: COC(=O)C1=C(C)NC(C)=C(C1c2cccc(NC(=O)NCCCN3CCC(CC3)c4cccc(OC)c4)c2)C(=O)OC
• InChI: 1S/C33H42N4O6/c1-21-28(31(38)42-4)30(29(22(2)35-21)32(39)43-5)25-10-6-11-26(19-25)36-33(40)34-15-8-16-37-17-13-23(14-18-37)24-9-7-12-27(20-24)41-3/h6-7,9-12,19-20,23,30,35H,8,13-18H2,1-5H3,(H2,34,36,40)
• InChI key: WMYSXJSJXZFODY-UHFFFAOYSA-N

설명

생화학적/생리학적 작용

BMS-193885 is a potent, selective Y1 antagonist that is active in both acute and chronic animal models of food intake. Although it is active in vivo, it is not orally bioavailable due to poor intestinal absorption, so it is not being pursued for pharmaceutical development. BMS-193885 has been used as a pre-clinical proof of concept tool for showing efficacy of Y1 antagonism in treating obesity.

특징 및 장점

This compound is featured on the Neuropeptide Y Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• 픽토그램: GHS07
• 신호어: Warning
• 유해 및 위험 성명서: H302
• 예방조치 성명서: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable